Increased secretion of amylin in women with polycystic ovary syndrome
Abstract
OBJECTIVE: To investigate amylin secretion in women with polycystic ovary syndrome (PCOS).
DESIGN: Prospective, case-control study.
SETTING: Academic institution.
PATIENT(S): Twenty women with PCOS and 10 with ovulatory cycles who matched for body mass index.
INTERVENTION(S): An oral glucose tolerance test was performed, and glucose, insulin, and amylin levels were measured at fasting and after glucose ingestion. The area under the curve for insulin, amylin, and glucose was calculated. Ten women with PCOS were treated with metformin and 10 women with rosiglitazone for 6 months. Amylin levels were measured before and after treatment.
RESULT(S): Fasting amylin levels and amylin response to oral glucose were significantly increased in women with PCOS. At fasting, there was significant positive correlation between insulin and amylin levels both in women with PCOS and control subjects. After glucose ingestion, amylin response correlated with the glucose response in women with PCOS. Amylin levels decreased with metformin but not with rosiglitazone treatment.
CONCLUSION(S): In women with PCOS, [1] there is increased secretion of amylin, [2] insulin and amylin secretion is coregulated in the fasting state, [3] after glucose ingestion, glucose levels regulate amylin release, and [4] the insulin-sensitizing agent metformin, but not rosiglitazone, reduces amylin secretion.
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 10 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.